Teva announces first approval and launch of Generic Lovaza® capsules in the United States
9 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza®...
List view / Grid view
News
Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) submitted to the U.S. FDA
9 April 2014 | By Johnson & Johnson
Janssen Research & Development, LLC (“Janssen”) today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. This regulatory submission is based on data from the Phase 3 RESONATE™ study in relapsed or…
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
OncoEthix presents Phase I interim results for novel anticancer compound OTX015 at AACR 2014
8 April 2014 | By OncoEthix
OncoEthix announced that the interim results from its ongoing Phase I clinical trial of OTX015, in patients with hematologic malignancies, were presented at the annual American Association of Cancer Research...
FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
EMA and Australian regulator strengthen collaboration in the area of orphan medicines
7 April 2014 | By The European Medicines Agency
In a meeting at the European Medicines Agency on 4 April 2014, the EMA’s Executive Director, Prof. Guido Rasi, and the National Manager of the Australian Therapeutic Goods AdministrationExternal link icon, Prof. John Skerritt, announced that the two regulators have agreed to share the full assessment reports...
Roche acquires IQuum to strengthen offerings in molecular diagnostics
7 April 2014 | By Roche
IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics...
Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged progression-free survival in patients with advanced breast cancer
7 April 2014 | By Pfizer
Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib...
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
7 April 2014 | By Novartis
Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign...
Amgen provides update on Phase 3 study of talimogene laherparepvec in patients with metastatic melanoma
7 April 2014 | By Amgen
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec...
Daiichi Sankyo agrees to vote its shares in Ranbaxy in favor of Sun Pharma’s Acquisition
7 April 2014 | By Daiichi Sankyo
Pursuant to the merger transaction announced between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd. announces that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100%...
Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics
7 April 2014 | By Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p
Subpoena for Ranbaxy’s Toansa Plant
7 April 2014 | By Daiichi Sankyo
Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014...
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
Merck receives 2014 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
4 April 2014 | By Merck
Merck announced that it has received an ENERGY STAR 2014 Partner of the Year – Sustained Excellence Award from the U.S...
